COX-2 specific inhibitors in NSAID-intolerant patients

International Journal of Immunopathology and Pharmacology

Volumn 16, Issue 2 SUPPL., 2003, Pages 11-16

  Picado, César ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Asthma; Celecoxib; COX 2; NSAID; Rofecoxib

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; LIPOXYGENASE INHIBITOR; MELOXICAM; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PEPTIDOLEUKOTRIENE; ROFECOXIB;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ASTHMA; BRONCHOSPASM; BRONCHUS MUCOSA; CELL HETEROGENEITY; DRUG INDUCED ASTHMA; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TOLERANCE; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME SPECIFICITY; FIBROBLAST; HUMAN; INHIBITION KINETICS; PAIN; PERIPHERAL CIRCULATION; PRECIPITATION; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROSTAGLANDIN SYNTHESIS; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT DISEASE; REVIEW; RHINITIS; SKIN MANIFESTATION; URTICARIA;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0142121514     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Widal M.F., P. Abram and J. Lermoyez. 1922. Anaphylaxie et idiosyncraise. Press Med. 119:48.
2. Samter M. and R.F.J. Beers. 1968. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann. Intern. Med. 68:975.
3. Stevenson D., M. Sanchez-Borges and A. Szczeklik. 2001. Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann. Allergy 87:177.
4. Szceklik A., E. Nizankowska and M. Duplaga. 2000. Natural history of aspirin-induced asthma. Eur. Respir. J. 16:432.
5. Szczeklik S. and D.D. Stevenson. 2003. Aspirin-induced asthma: Advances in pathogenesis, diagnosis, and management. J. Allergy Clin. Immunol. 111:1.
6. Picado C., J.A. Castillo, J.M. Montserrat, et al. 1989. Aspirin-intolerance as a precipitating factor of life-threatening attacks of asthma requiring mechanical ventilation. Eur. Resp. J. 2:127
7. Melillo G., G. Balzano, S. Bianco, et al. 2001. Oral and inhalation tests for the diagnosis of aspirin-induced asthma. Allergy 56:899.
8. Dahlén B. and O. Zetterström. 1990. Comparison of bronchial and peroral provocation with aspirin in aspirin-sensitive asthmatics. Eur. Respir. J. 3:527.
9. Nizankowska E., A. Bestynska-Krypel, A. Cmiel and A. Szczeklik. 2000. Oral and bronchial provocation tests with aspirin for the diagnosis of aspirin-induced asthma, Eur. Respir. J. 15:863.
10. Milewski M., L. Mastalerz, E. Nizankowska and A. Szczeklik. 1998. Nasal provocation test with lysine-aspirin for diagnosis of aspirin-sesntive asthmatics. J. Allergy Clin. Immunol. 101:581.
11. Casadevall J., J. Mullol and C. Picado. 2000. Intranasal challenge with aspirin in the diagnosis of aspirin sensitive asthma. Evaluation of nasal response by acoustic rhinometry. Thorax 55:921.
12. Castillo J.A. and C. Picado. 1986. Prevalence of aspirin-intolerance in a hospital population. Respiration 50:153.
13. Kasper L., K. Sladek, M. Duplaga, et al. 2003. Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland. Allergy (in press)
14. Hedman J., J. Kaprio, T. Poussa and M.M. Nieminen. 1999. Prevalence of asthma, aspirin intolerance, nasal polyposis an chronic obstructive pulmonary disease in a population-based study. Int. J. Epidemiol. 28:717.
15. Vally H., M.L. Taylor and P.J. Thompson. 2002. The prevalence of aspirin-intolerant asthma (AIA) in Australian asthmatic patients. Thorax 57:569.
16. Picado C., I. Ramis, J. Rosellò, J. Prat, O. Bulbena, V. Plaza, J.M. Montserrat and E. Gelpí. 1992. Release of peptide leukotriene into nasal secretions after local instillation of aspirin in aspirin-sensitive asthmatic patients. Am. Rev. Respir. Dis. 145:65.
17. Christie P.E., P. Tagari, A.W. Ford-Hutchinson, et al. 1991. Urinary leukotriene E4 concentrations increase after ASA challenge in ASA-sensitive subjects. Am. Rev. Respir. Dis. 143:1025.
18. Kumlin M., B. Dahlén, T. Björck, O. Zetterström, E. Granström and S.E. Dahlén. 1992. Urinary excretion of leukotriene E4 and 11-dehydro-tromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4 and histamine in asthmatics. Am. Rev. Respir. Dis. 146:96
19. Szczeklik A. 1990. The cyclooxygenase theory of aspirin-induced asthma. Eur. Respir. J. 3:339.
20. Picado C. 2002. Aspirin-intolerant asthma: role of cyclo-oxygenase enzymes. Allergy 57 (S72):58.
21. Picado C., F. Fernandez-Morata, M. Juan, et al. 1999. Cycloxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. Am. J. Respir. Crit. Care Med. 160:291.
22. Kowalski M.L., R. Pawliczak, J. Wozniak, et al. 2000. Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am. J. Respir. Crit. Care Med. 161:391.
23. Pierzchalska M., Z. Szabo, M. Sanak, J. Soja and A. Szczeklik. 2003. Deficient prostaglandin E2 production by bronchial fibroblasts of asthmatic patients with special reference to aspirin-induced asthma, J. Allergy Clin. Immunol. 111:913.
24. Schäfer D., M. Schmid, U.C. Göde and H.W. Baenkler. 1999. Dynamics of eicosanoids in peripheral blood cells during bronchial provocation in aspirin-intolerant asthmatics. Eur. Respir. J. 13:638
25. Sanak M., B.D. Levy, C.B. Clish, et al. 2000. Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur. Respir. J. 16:44.
26. Sestini P., L. Armetti, G. Gambaro, et al. 1996. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am. J. Respir. Crit. Care Med. 153:572.
27. Picado C., G. Bioque, J. Roca-Ferrer, et al. 2003. Nuclear factor-kB activity is down-regulated in nasal polyps from aspirin-sensitive asthmatics. Allergy 58:122.
28. Settipane R.A., P.J. Schrank, R.A. Simon, et al. 1995. Prevalence of cross-sensitivity with acetaminophen in aspirin-sensitive asthmatic subjects. J. Allergy Clin. Immunol. 96:480.
29. Valero Santiago A., E. Gonzalez-Morales and E. Martin Guadaño. 2003. Tolerance of nimesulide in NSAID intolerant patients. Allergy 58:367.
30. Andri L., G.E. Senna, C. Beteli, et al. 1994. Tolerability of nimesulide in aspirin-sensitive patients. Ann. Allergy 72:29.
31. Quarantino D., A. Romano, G. Papa, et al. 1997. Long-tem tolerability of nimesulide and acetaminophen in non-steroidal anti-inflammatory drug-intolerant patients. Ann. Allergy Asthma Immunol. 79:47.
32. Kosnik M., E. Music, F. Matjaaz, et al. 1988. Relative safety of meloxicam in NSAID-intolerant patients. Allergy 53:1231.
33. Quarantino D., A. Romano, M. Di Fonso, et al. 2000. Tolerability of meloxicam in patients with histories of adverse reactions to nonsteroidal anti-inflammatory drugs. Ann. Allergy Asthma Immunol. 84:613.
34. Szczeklik A., E. Nizankowska, G. Bochenek, et al. 2001. Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin. Exp. Allergy 31:219
35. Stevenson D.D. and R.A. Simon. 2001. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J. Allergy Clin. Immunol. 108:47
36. Martin-García C., M. Hinojosa, P. Berges, et al. 2002. Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. Chest 121:1812.
37. Gyllfords P., G. Bochenek, J. Overholt, et al. 2003. Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgesic drug celecoxib. J. Allergy Clin. Immunol. 111:1116
38. Valero A., M. Baltasar, E. Enrique et al. 2002. NSAID-sensitive patients tolerate rofecoxib. Allergy 57:1214.
39. Sánchez-Borges M., A. Capriles-Hulett, F. Caballero-Fonseca and C.R. Perez. 2001. Tolerability of new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Ann. Allergy Asthma Immunol. 87:201.